PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION

Keywords

MedicineWarfarinAspirinPlaceboAtrial fibrillationStroke (engine)Clinical endpointIncidence (geometry)SurgeryInternal medicineComplicationAnesthesiaRandomized controlled trialCardiology

Affiliated Institutions

Related Publications

Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Gregory W. Albers , Hans‐Christoph Diener , Lars Frison +8 more

The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in pat...

2005 JAMA 660 citations

Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin

E.L.L.M. De Schryver

The ESPRIT trial addresses the problem that aspirin, the standard therapy for secondary prevention of vascular complications after a transient ischaemic attack (TIA) or ischaemi...

2000 Cerebrovascular Diseases 98 citations

Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris

Steen Juul‐Möller , Nils Edvardsson , B Jahnmatz +3 more

Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) is ...

1992 The Lancet 511 citations

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel , Kenneth W. Mahaffey , Jyotsna Garg +13 more

In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group differenc...

2011 New England Journal of Medicine 9184 citations

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation

Pooja Khatri , Ron Neyens , Mintu P. Turakhia +5 more

T he rate of stroke among adults with atrial fibrilla- tion (AF) varies widely, ranging between 1% and 20% annually (mean 4.5% per year) depending on comorbidities and a patient...

2012 Stroke 269 citations

Publication Info

Year: 1989
Type: article
Volume: 333
Issue: 8631
Pages: 175-179
Citations: 1824
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1824

OpenAlex

Cite This

APA Style

                            
                                
                                    Palle Petersen, 
                                
                                    J Godtfredsen, 
                                
                                    Gudrun Boysen
                                
                                et al.
                            
                            (1989). 
                            PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION. 
                            The Lancet
                            , 333
                            (8631)
                            , 175-179.
                            https://doi.org/10.1016/s0140-6736(89)91200-2
                        

Identifiers

DOI: 10.1016/s0140-6736(89)91200-2